Ultragenyx turns rare disease approvals into $413 million in cash
Ultragenyx Pharmaceutical has converted two recent priority review vouchers into a large non-dilutive cash infusion, signing separate agreements to sell the regulatory assets for a combined $413 million. One voucher was sold for $203 million and the other for $210 million, after the company received them alongside FDA approvals for two gene therapies in late August and mid-September.
The transactions arrive at a decisive moment for the Novato, California-based biotech. Recent gene therapy approvals expanded its commercial footprint, but they did not change the company’s central financial challenge: building a durable pipeline in rare disease while absorbing the loss of a late-stage program that had carried much of the company’s longer-term value expectations.
How the voucher program became a financing tool
Congress created the rare pediatric disease voucher program to encourage drug development in conditions with small patient populations and limited commercial incentive. When a company wins FDA approval in an eligible rare pediatric disease, it receives a voucher that can shorten the next review cycle from the standard 10 months to six. The voucher can be used internally or sold, and Ultragenyx chose the latter path twice in rapid succession.
The buyers were not disclosed, and both transactions still must satisfy closing conditions. Even so, the pricing tells its own story. Demand for these regulatory fast passes has pushed values higher, and most vouchers sold this year have crossed the $200 million mark. In a market where time to approval can reshape launch economics and competitive positioning, a shortened review period is worth real capital.
One sentence captures the business logic: Ultragenyx traded regulatory acceleration for immediate balance-sheet strength.
Two gene therapy approvals, two first-in-disease products
Each voucher came attached to a recent gene therapy approval for an ultra-rare inherited enzyme deficiency. The late-August approval covered Gengylcos, a gene therapy for glycogen storage disease type Ia, while the mid-September approval covered Fayuvi, a gene therapy for Sanfilippo syndrome type A. In both cases, the therapies became the first approved options for their respective indications.
That matters clinically because first-in-class approval in an ultra-rare disease is not just a regulatory milestone; it can alter the treatment conversation for families and clinicians who have had little beyond supportive care or symptom management. It also matters commercially, although not always in the way investors imagine. Ultra-rare therapies can command multimillion-dollar price tags and still remain too small to drive broad revenue growth at a large-company scale.
The company’s financial future had been leaning heavily on a very different asset: apazunersen, an antisense oligonucleotide in development for Angelman syndrome. That program failed in Phase 3 last month, and the setback triggered a corporate restructuring and expense reduction plan. The contrast is stark. Two regulatory approvals brought in vouchers that can be monetized immediately, while the asset once expected to anchor future growth fell short in late-stage testing.
Pipeline strategy after the Angelman setback
Ultragenyx did not disclose how it plans to deploy the voucher proceeds, but the balance-sheet effect is straightforward. As of the end of June, the company reported $436 million in cash. The new $413 million in voucher sales could materially strengthen its ability to pursue another rare disease asset, whether through licensing, acquisition, or another structured business deal.
The company has used this playbook before. Ultragenyx previously received vouchers tied to rare disease approvals in 2017 and 2018, and Chief Financial Officer Howard Horn said the Sanfilippo gene therapy benefited from capital generated by an earlier voucher sale. His comment framed the program as a financing mechanism that feeds the next round of therapy development, not merely a reward for past success.
For a rare disease company, that cycle can be unusually important. Drug development in these settings often depends on long timelines, high scientific uncertainty, and a narrow investor appetite for assets that may never produce conventional blockbuster revenue. Non-dilutive capital from voucher sales avoids the immediate ownership dilution that comes with fresh equity issuance, while preserving flexibility for future pipeline expansion.
What investors will watch next
The voucher sales improve Ultragenyx’s financial position, but they do not erase the questions raised by the apazunersen failure. William Blair analyst Lachlan Hanbury-Brown said in a Wednesday research note that the company’s pipeline lacks clinical catalysts capable of driving stock value over the next year, even after the launch of two new gene therapies. He said the voucher sales significantly bolster the balance sheet and could help the company reach generally accepted accounting principles profitability in 2027 if management executes its expense reduction plans.
The next milestone is not scientific; it is strategic. Investors will be watching for how management deploys the new capital, whether additional rare disease deals follow, and how deeply the restructuring affects future R&D capacity. Ultragenyx is expected to report third-quarter 2026 financial results in November.
The central tension remains visible in the numbers. The company has turned two ultra-rare approvals into $413 million in cash, but its most important next move may be finding the right new asset before the window closes on its current cash runway and pipeline reset.